CoChat

Acetylcholinesterase inhibitors for schizophrenia

Open access
Singh, Jasvinder, Kour, Kamalpreet, Jayaram, Mahesh B · 2012 · Cochrane Database of Systematic Reviews
Cited by 67

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Antipsychotic medication remains the mainstay of treatment for schizophrenia and has been in use for a long time. As evidenced by ongoing research and partial effectiveness of the antipsychotics on cognitive and negative symptoms, the search is on for drugs that may improve these domains of functioning for someone suffering from schizophrenia. Acetylcholinesterase inhibitors have long been in use for treating cognitive symptoms of dementia. OBJECTIVES: The aim of the review was to evaluate the clinical effects, safety and cost effectiveness of acetylcholinesterase inhibitors for treating people with schizophrenia SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Register (February 2009), and inspected the references of all identified studies for further trials. SELECTION CRITERIA: We included all clinical randomised trials comparing acetylcholinesterase inhibitors with antipsychotics or placebo either alone, or in combination, for schizophrenia and schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data, we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat (ITT) basis based on a random-effects model. For continuous data, we calculated mean differences (MD), again based on a random-effects model. MAIN RESULTS: The acetylcholinesterase inhibitor plus antipsychotic showed benefit over antipsychotic and placebo in the following outcomes.1. Mental state - PANSS negative symptoms average end point score (2 RCTs, n = 31, MD -1.69 95% CI -2.80 to -0.57), PANSS General Psychopathology average end point score (2 RCTs, n = 31, MD -3.86 95% CI -5.40 to -2.32), and improvement in depressive symptoms showed at least by one short-term study as measured by CDSS scale (data skewed).2. Cognitive domains - attention, (1 RCT, n = 73, MD 1.20 95% CI 0.14 to 2.26), visual memory (2 RCTs, n = 48 , MD 1.90 95% CI 0.52 to 3.28), verbal memory and language (3 RCTs, n = 42, MD 3.46 95% CI 0.67 to 6.26) and executive functioning (1 RCT, n = 24, MD 17.10 95% CI 0.70 to 33.50).3. Tolerability - EPSE: AIMS, (1 RCT, n = 35, MD 1.50 95% CI 1.04 to 1.96).No difference was noted between the two arms in other outcomes. The overall rate of participants leaving studies early was low (13.6 %) and showed no clear difference between the two groups. AUTHORS' CONCLUSIONS: The results seem to favour the use of acetylcholinesterase inhibitors in combination with antipsychotics on a few domains of mental state and cognition, but because of the various limitations in the studies as mentioned in the main text, the evidence is weak. This review highlights the need for large, independent, well designed, conducted and reported pragmatic randomised studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd007967.pub2

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 99

  1. Akhondzadeh, 2008, A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 1810, 10.1016/j.pnpbp.2008.08.001 · DOI
  2. Boggs, 2007, Galantamine does not significantly effect positive or negative symptoms in patients with schizophrenia, Schizophrenia Bulletin, 33, 422
  3. Boggs DL Conley RR Nelson MW Feldman S Ball P McMohan RP Buchanan RW Galantamine does not significantly effect positive or negative symptoms in with schizophrenia Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1, Colorado Springs, Colorado, USA 2007
  4. Buchanan, 2007, Galantamine for the treatment of cognitive impairments in patients with schizophrenia, Schizophrenia Bulletin, 33, 424
  5. Caroff, 2007, Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial, Journal of Clinical Psychiatry, 68, 410, 10.4088/JCP.v68n0309 · DOI
  6. Chouinard, 2007, Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits, Current Medical Research and Opinion, 23, 575, 10.1185/030079906X167372 · DOI
  7. Guillem, 2006, Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30, 934, 10.1016/j.pnpbp.2006.02.009 · DOI
  8. Dyer, 2008, High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia, Schizophrenia Research, 102, 88, 10.1016/j.schres.2007.12.491 · DOI
  9. Fagerlund, 2007, Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study, Clinical Neuropharmacology, 30, 3, 10.1097/01.WNF.0000240940.67241.F6 · DOI
  10. Freudenreich, 2005, Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial, Psychopharmacology, 181, 358, 10.1007/s00213-005-2235-1 · DOI
  11. Friedman, 2002, A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia, Biological Psychiatry, 51, 349, 10.1016/S0006-3223(01)01342-7 · DOI · Paper page
  12. Friedman, 2002, A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia, Schizophrenia Research, 53, 9
  13. Friedman JI Adler DN Howanitz E Temporini H Harvey PD Davis KL Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000
  14. Friedman, 2001, Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia, Schizophrenia Research, 49, 228
  15. Keefe, 2008, Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial, Neuropsychopharmacology, 33, 1217, 10.1038/sj.npp.1301499 · DOI
  16. Kim, 2005, A 12 week, double - blind, placebo controlled trial of donepezil adjunctive to haloperidol for the cognitive impairments in patients with chronic schizophrenia, Schizophrenia Bulletin, 31, 490
  17. Kim YH Lee BJ A 12 week, double-blind, placebo controlled trial of donepezil adjunctive to haloperidol for the cognitive impairments in patients with chronic schizophrenia Proceedings of the XIII World Congress of Psychiatry; 2005 10-15th Sept; Cairo, Egypt 2005
  18. Lee, 2007, A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia, Journal of Psychopharmacology, 21, 421, 10.1177/0269881106070996 · DOI
  19. Kohler, 2007, No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia, Cognitive Neuropsychiatry, 12, 412, 10.1080/13546800701307263 · DOI
  20. Lee, 2005, A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for cognitive impairments in chronic schizophrenia, Clinical Psychopharmacology and Neuroscience, 3, 10
  21. Lee, 2007, A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia, International Clinical Psychopharmacology, 22, 63, 10.1097/YIC.0b013e3280117feb · DOI
  22. Nahas, 2003, Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study, Neurocase, 9, 274, 10.1076/neur.9.3.274.15563 · DOI
  23. Schubert, 2006, Galantamine improves cognition in schizophrenic patients stabilized on risperidone, Biological Psychiatry, 60, 530, 10.1016/j.biopsych.2006.04.006 · DOI
  24. Schubert, 2005, Cognitive improvement in schizophrenia and schizoaffective disorder by augmentation of risperidone with galantamine, Schizophrenia Bulletin, 31, 503
  25. Aasen, 2005, Effects of rivastigmine on sustained attention in schizophrenia: an fMRI study, Journal of Clinical Psychopharmacology, 25, 311, 10.1097/01.jcp.0000169267.36797.76 · DOI
  26. Aasen, 2004, Enhanced attention with rivastigmine in schizophrenia: an fmri study, Schizophrenia Research, 67, 140
  27. Kumari, 2006, Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study, Neuroimage, 29, 545, 10.1016/j.neuroimage.2005.08.013 · DOI
  28. Kumari, 2004, Neural correlates of rivastigmine treatment in schizophrenia: an fMRI study, European Neuropsychopharmacology, 14, S286, 10.1016/S0924-977X(04)80344-4 · doi:10.1016/s0924-977x(04)80344-4
  29. Sharma, 2004, A placebo-controlled double-blind investigation of cognitive effects of rivastigmine in schizophrenia, Schizophrenia Research, 67, 208
  30. Sharma, 2004, A placebo-controlled double-blind investigation of cognitive effects of rivastigmine in schizophrenia, European Neuropsychopharmacology, 14, S284, 10.1016/S0924-977X(04)80339-0 · doi:10.1016/s0924-977x(04)80339-0
  31. Sharma, 2006, Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation, Schizophrenia Research, 85, 73, 10.1016/j.schres.2006.03.037 · DOI
  32. Tugal, 2004, A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia, International Journal of Neuropsychopharmacology, 7, 117, 10.1017/S1461145703004024 · DOI · Paper page
  33. Tugal, 2003, A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for the cognitive impairment of schizophrenia, European Neuropsychopharmacology, 13, S294
  34. Tuma, 2003, Donepezil as an adjunctive treatment of cognitive dysfunction in schizophrenia, European Neuropsychopharmacology, 13, S348, 10.1016/S0924-977X(03)92110-9 · doi:10.1016/s0924-977x(03)92110-9
  35. Tuma I Lenderova Z Zemanova M Kadlecova E Perez M Donepezil as an adjunctive treatment of cognitive dysfunction in schizophrenia Proceedings of the16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic 2003
  36. Davis, 1981, Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion, Psychopharmacology, 72, 155, 10.1007/BF00431649 · DOI
  37. Edelstein, 1981, Physostigmine and lithium response in the schizophrenias, American Journal of Psychiatry, 138, 1078, 10.1176/ajp.138.8.1078 · DOI
  38. El-Yousef, 1973, Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study, American Journal of Psychiatry, 130, 1973, 10.1176/ajp.130.2.141 · DOI
  39. Ingram, 1983, The use of tacrine for tardive dyskinesia, American Journal of Psychiatry, 140, 1629, 10.1176/ajp.140.12.1629 · doi:10.1176/ajp.140.12.1629
  40. Janowsky, 1973, The elicitation of psychotic symptomatology by methylphenidate, 113
  41. Janowsky, 1973, Antagonistic effects of physostigmine and methylphenidate in man, American Journal of Psychiatry, 130, 1370, 10.1176/ajp.130.12.1370 · DOI · Paper page
  42. Janowsky, 1973, Parasympathetic suppression of manic symptoms by physostigmine, Archives of General Psychiatry, 28, 542, 10.1001/archpsyc.1973.01750340072012 · DOI · Paper page
  43. Kristiansen, 2001, Effects of antipsychotics and other agents on prepulse inhibition of the startle response (ppi), Schizophrenia Research, 49, 216
  44. Lieberman, 1988, Pharmacologic characterization of tardive dyskinesia, Journal of Clinical Psychopharmacology, 8, 254, 10.1097/00004714-198808000-00004 · DOI
  45. Mazeh, 2006, Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study, International Psychogeriatrics, 18, 429, 10.1017/S1041610205003017 · DOI
  46. Moore, 1980, Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes, American Journal of Psychiatry, 137, 1202, 10.1176/ajp.137.10.1202 · doi:10.1176/ajp.137.10.1202
  47. Okereke CS Kumar D Cullen EI Pratt RD Hahne WF Safety and pharmacokinetics profile of concurrent donepezil hcl and levodopa/carbidopa Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002
  48. Ophir, 2004, Rivastigmine therapy for memory deficits in schizophrenia patients receiving electroconvulsive treatment, European Neuropsychopharmacology, 14, S126, 10.1016/S0924-977X(04)80026-9 · doi:10.1016/s0924-977x(04)80026-9
  49. Pesco-Koplowitz L Parier J-L Zhao Q Heron J Pharmacokinetics of risperidone/donepezil combination Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico 1999
  50. Pesco-Koplowitz, 2000, Pharmacokinetics of risperidone/donepezil combination, Biological Psychiatry, 47, 167S, 10.1016/S0006-3223(00)00818-0 · doi:10.1016/s0006-3223(00)00818-0
  51. Risch, 1981, Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates, Journal of Clinical Psychopharmacology, 1, 186, 10.1097/00004714-198107000-00003 · DOI · Paper page
  52. Risch, 2001, A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates, Neurocase, 7, 105, 10.1093/neucas/7.2.105 · doi:10.1093/neucas/7.2.105
  53. Stryjer, 2004, Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study, Human Psychopharmacology, 19, 343, 10.1002/hup.595 · DOI
  54. Tamminga, 1977, Cholinergic influences in tardive dyskinesia, American Journal of Psychiatry, 134, 769, 10.1176/ajp.134.7.769 · DOI
  55. Hussain MZ Chaudhry ZA Rivastigmine and galantamine treatment for schizophrenic cognitive impairment Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003
  56. Hussain MZ Chaudhry ZA Rivastigmine and galantamine treatment of schizophrenic cognitive impairment Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA 2004
  57. Kelleher JP Shinnar MR Olshanskiy V Malhotra A Kane J Sonnenberg M Lascher S Galantamine treatment of comorbid nicotine dependence in patients with schizophrenia or schizoaffective disorder Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA 2008
  58. Modestin, 1973, Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl), Pharmakopsychiatrie und Neuropsychopharmakologie, 6, 300, 10.1055/s-0028-1094395 · DOI
  59. Addington, 1993, Assessing depression in schizophrenia: the Calgary Depression Scale, British Journal of Psychiatry, 22, 39, 10.1192/S0007125000292581 · DOI · Paper page
  60. Andreasen, 1984, Scale for the Assessment of Positive Symptoms (SAPS)
  61. Andreasen, 1989, Scale for the assessment of negative symptoms (SANS), British Journal of Psychiatry, 7, 53
  62. Barnes, 1989, A rating scale for drug-induced akathisia, British Journal of Psychiatry, 154, 672, 10.1192/bjp.154.5.672 · DOI · Paper page
  63. Benedict, 1996, Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity, Psychological Assessment, 8, 145, 10.1037/1040-3590.8.2.145 · DOI · Paper page
  64. Bland, 1997, Statistics notes. Trials randomised in clusters, BMJ, 315, 600, 10.1136/bmj.315.7108.600 · DOI · Paper page
  65. Boissel, 1999, The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use, Therapie, 54, 405
  66. Carpenter, 1994, Schizophrenia, New England Journal of Medicine, 10, 681, 10.1056/NEJM199403103301006 · DOI · Paper page
  67. Chouinard, 1993, Clinical review of risperidone, Canadian Journal of Psychiatry, 38, 89
  68. Conners, 2000, Connersê Continuous Performance Test II: Computer Program for Windows Technical Guide and Software Manual
  69. Craig JC Webster AC Loy C How long should treatments be continued? BMJ 2010 c4102 · DOI
  70. Deeks JJ Issues in the selection of a summary statistic for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa Cape Town Cochrane Collaboration 2000
  71. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
  72. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 13, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  73. Gulliford, 1999, Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology, 149, 876, 10.1093/oxfordjournals.aje.a009904 · DOI · Paper page
  74. Guy, 1976, ECDEU assessment manual for psychopharmacology
  75. Hamilton, 1980, Rating depressive patients, Journal of Clinical Psychiatry, 41, 21
  76. Heaton, 1993, Wisconsin Card Sorting Test Manual: Revised and Expanded, Psychological Assessment Resources
  77. Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine, American Journal of Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 · DOI · Paper page
  78. Kang, 1997, A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients, Korean Neurological Association, 15, 300
  79. Kay, 1986, Positive and Negative Syndrome Scale (PANSS) Manual
  80. Kay, 1987, Positive and negative syndrome scale (PANSS) manual, Schizophrenia Bulletin, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
  81. Matthews, 1964, Instruction Manual for the Adult Neuropsychology Test Battery
  82. Komossa, 2010, Quetiapine versus other atypical antipsychotics for schizophrenia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006625.pub2 · DOI · Paper page
  83. Michael, 2007, Cognition as an outcome measure in schizophrenia, British Journal of Psychiatry, 191, s46
  84. Leucht, 2005, What does the PANSS mean?, Schizophrenia Research, 79, 231, 10.1016/j.schres.2005.04.008 · DOI · Paper page
  85. Meyers, 1995, Rey Complex Figure Test and Recognition Trial: Professional Manual
  86. Overall, 1962, The brief psychiatric rating scale, Psychological Reports, 10, 799, 10.2466/pr0.1962.10.3.799 · DOI · Paper page
  87. Randolph C Repeatable battery for the assessment of neuropsychological status Psychological Corporation 1998 · DOI · Paper page
  88. Shekhar, 2008, Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia, American Journal of Psychiatry, 165, 1033, 10.1176/appi.ajp.2008.06091591 · DOI · Paper page
  89. Simpson, 1970, A rating scale for extrpyramidal side-effects, Acta Psychiatrica Scandinavica Supplementum, 212, 11, 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
  90. Smith, 2003, Medical journals and pharmaceutical companies: uneasy bedfellows, BMJ, 326, 1202, 10.1136/bmj.326.7400.1202 · DOI
  91. Stahl, 2000, Psychopharmacology of reward and drugs of abuse, 469
  92. Stroop, 1935, Studies of interference in serial verbal reactions, Journal of Experimental Psychology, 18, 643, 10.1037/h0054651 · DOI · Paper page
  93. Ukoumunne, 1999, Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review, Health Technology Assessment, 3, iii, 10.3310/hta3050 · DOI · Paper page
  94. Wechsler, 1997, Wechsler Adult Intelligence Scale- Administration And Scoring Manual
  95. Wechsler, 1997, Wechsler Memory Scale- Administration and Scoring Manual
  96. Wilk, 2002, Test and retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia, American Journal of Psychiatry, 159, 838, 10.1176/appi.ajp.159.5.838 · DOI · Paper page
  97. Winkler, 1998, Cholinergic strategies for alzheimer's disease, Journal of Molecular Medicine, 76, 555, 10.1007/s001090050250 · DOI · Paper page
  98. Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H Pinfold V Takriti Y The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo 2007
  99. Yeomans, 1995, Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia, Neuropsychopharmacology, 12, 3, 10.1038/sj.npp.1380235 · doi:10.1038/sj.npp.1380235 · Paper page

Cited by

See all 67

Metadata

Authors
Singh, J., Kour, K., & Jayaram, M. B.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2012-01-18
Volume
2012
Issue
11
Pages
CD007967-CD007967
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1916719536
Cited by
67
References
17
FWCI
3.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acetylcholinesterase inhibitors for schizophrenia. https://app.cochat.ai/papers/10.1002/14651858.cd007967.pub2
The paper
Singh, J., Kour, K., & Jayaram, M. B. (2012). Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd007967.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.